Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL -1.79%48 PS Ratio is 13.61 as of Jul. 14, 2026, which is 56% below its 10-year median of 30.79. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.90 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 806 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 87.59% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, OncoSil Medical's share price is A$1.375.
OncoSil Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.10. Hence, OncoSil Medical's PS Ratio for today is 13.61.
The historical rank and industry rank for OncoSil Medical's PS Ratio or its related term are showing as below:
ASX:OSL'
s PS Ratio Range Over the Past 10 Years
Min: 4.07 Med: 30.79 Max: 259.51
Current: 13.61
During the past 13 years, OncoSil Medical's highest PS Ratio was 259.51. The lowest was 4.07. And the median was 30.79.
ASX:OSL's PS Ratio is ranked worse than 87.59% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 2.88
vs ASX:OSL: 13.61
OncoSil Medical Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of OncoSil Medical was -15.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.10% per year.
During the past 13 years, OncoSil Medical's highest 3-Year average Revenue per Share Growth Rate was 7.10% per year. The lowest was -7.40% per year. And the median was 1.05% per year.
Back to Basics: PS Ratio
OncoSil Medical (ASX:OSL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
OncoSil Medical PS Ratio Related Terms
OncoSil Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, OncoSil Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
OncoSil Medical's Share Price of today is A$1.375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OncoSil Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
OncoSil Medical (ASX:OSL) has a PS Ratio of 13.61 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on OncoSil Medical and its competitors. This is 56% below median its historical median of 30.79. Over the past decade, OncoSil Medical's PS Ratio has ranged from 4.07 to 259.51. According to the industry distribution chart, OncoSil Medical ranks #706 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 87.6%.
Is OncoSil Medical's PS Ratio too high?
OncoSil Medical's current PS Ratio of 13.61 is 56% below median its 10-year median of 30.79. Over the past 10 years, this metric has ranged from a low of 4.07 to a high of 259.51. The Medical Devices & Instruments industry median PS Ratio is 2.88. OncoSil Medical's value of 13.61 is 372.6% above this industry median. Based on the distribution chart, OncoSil Medical ranks #706 out of 806 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #706 out of 806 companies for PS Ratio. This places OncoSil Medical in the lower half of its industry. The industry median PS Ratio is 2.88. OncoSil Medical's value of 13.61 is 372.6% above this benchmark. Historically, OncoSil Medical's own PS Ratio has ranged from 4.07 to 259.51 over the past decade. While the company's 10-year median is 30.79 vs. the industry median of 2.88, OncoSil Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.88, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSil Medical's current PS Ratio of 13.61 is 372.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current PS Ratio is 13.61, which is 56% below median its own 10-year median of 30.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current PS Ratio is 13.61, which is 56% below median its 10-year median of 30.79 and 372.6% above the Medical Devices & Instruments industry median of 2.88. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current PS Ratio is 13.61 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
PS Ratio: 13.61 (56% below median its 10-year median of 30.79)
GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
Industry Position: 372.6% above the Medical Devices & Instruments median (#706 of 806)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score
Get the complete analysis for ASX:OSL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
